Amendments to the Claims:

Please cancel claims 1-8 and 10-14.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-8. (canceled)

9. (currently amended) ~~A~~ An *in vitro* method of targeting a targeting vector into mouse ES cells~~,~~ comprising introducing into the ~~ES~~ cells a targeting vector comprising ~~a drug resistance gene under control of~~ a ubiquitin promoter.

10-14. (canceled)

15. (original) The method of claim 9, wherein the ubiquitin promoter is the ubiquitin C promoter.

16. (original) The method of claim 15, wherein the ubiquitin promoter is a human, mouse, rat, or bacterial ubiquitin promoter.

17. (new) An *in vitro* method of directing a targeting vector to a specific chromosomal location within a genome of a mouse embryonic stem (ES) cell, comprising introducing into the cell a targeting vector, wherein the targeting vector comprises a drug resistance gene under control of a ubiquitin promoter.

18. (new) The method of claim 17, wherein the ubiquitin promoter is the ubiquitin C promoter.

19. (new) The method of claim 18, wherein the ubiquitin promoter is a human, mouse, rat, or bacterial ubiquitin promoter.

20. (new) The method of claim 17, wherein the drug resistance gene encodes one of neomycin phosphotransferase, hygromycin phosphotransferase, or puromycin acetyl transferase.

21. (new) A targeting vector comprising a drug resistance gene under control of a ubiquitin promoter.

22. (new) The targeting vector of claim 21, wherein the ubiquitin promoter is the ubiquitin C promoter.

23. (new) The targeting vector of claim 22, wherein the ubiquitin promoter is a human, mouse, rat, or bacterial ubiquitin promoter.

24. (new) The targeting vector of claim 21, wherein the drug resistance gene encodes one of neomycin phosphotransferase, hygromycin phosphotransferase, or puromycin acetyl transferase.